Frontiers in Immunology (May 2023)
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
- Yixing Wang,
- Yixing Wang,
- Yixing Wang,
- Sha Fu,
- Sha Fu,
- Xuanye Zhang,
- Xuanye Zhang,
- Xuanye Zhang,
- Wei Du,
- Wei Du,
- Wei Du,
- Linfeng Luo,
- Linfeng Luo,
- Linfeng Luo,
- Yongluo Jiang,
- Yongluo Jiang,
- Yongluo Jiang,
- Yixin Zhou,
- Yixin Zhou,
- Yixin Zhou,
- Yuanyuan Zhao,
- Yuanyuan Zhao,
- Yuanyuan Zhao,
- Yunpeng Yang,
- Yunpeng Yang,
- Yunpeng Yang,
- Hongyun Zhao,
- Hongyun Zhao,
- Hongyun Zhao,
- Wenfeng Fang,
- Wenfeng Fang,
- Wenfeng Fang,
- Yan Huang,
- Yan Huang,
- Yan Huang,
- Li Zhang,
- Li Zhang,
- Li Zhang,
- Shaodong Hong,
- Shaodong Hong,
- Shaodong Hong
Affiliations
- Yixing Wang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yixing Wang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yixing Wang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Sha Fu
- Department of Cellular & Molecular Diagnostics Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
- Sha Fu
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation of Sun Yat-Sen University, Guangzhou, China
- Xuanye Zhang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Xuanye Zhang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Xuanye Zhang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Wei Du
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Wei Du
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Wei Du
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Linfeng Luo
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Linfeng Luo
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Linfeng Luo
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Yongluo Jiang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yongluo Jiang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yongluo Jiang
- Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
- Yixin Zhou
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yixin Zhou
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yixin Zhou
- Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, China
- Yuanyuan Zhao
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yuanyuan Zhao
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yuanyuan Zhao
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Yunpeng Yang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yunpeng Yang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yunpeng Yang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Hongyun Zhao
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Hongyun Zhao
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Hongyun Zhao
- Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China
- Wenfeng Fang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Wenfeng Fang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Wenfeng Fang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Yan Huang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Yan Huang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Yan Huang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Li Zhang
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Li Zhang
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Li Zhang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Shaodong Hong
- State Key Laboratory of Oncology in South China, Guangzhou, China
- Shaodong Hong
- Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- Shaodong Hong
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1151385
- Journal volume & issue
-
Vol. 14
Abstract
ObjectiveFew data are available on the optimal treatment options after disease progression from first-line treatment of immune checkpoint inhibitors (ICIs) plus chemotherapy. This study aimed to describe the safety and efficacy of continuing ICIs beyond first progress disease (PD) in non-small cell lung cancer (NSCLC).MethodsPatients with NSCLC previously treated with first-line anti-PD-1 antibody plus platinum-doublet chemotherapy and hence had PD as per Response Evaluation Criteria in Solid Tumors v1.1 were enrolled. For the subsequent line, patients received physician’s choice (PsC) with or without an anti-PD-1 antibody. The primary outcome was progression-free survival after second-line treatment (PFS2). Secondary outcomes included overall survival (OS) from the initiation of first-line treatment, post-second-progression survival (P2PS), overall response rate (ORR), disease control rate (DCR), and safety during second-line treatment.ResultsBetween July 2018 and January 2021, 59 patients were included. A total of 33 patients received a physician-decided second-line regimen plus ICIs (PsC plus ICIs group), and 26 patients did not continue ICIs (PsC group). There was no significant difference in PFS2 between the PsC plus ICIs group and the PsC group (median, 6.5 vs. 5.7 months, p = 0.46). median OS (28.8 vs. 29.2 months), P2PS (13.4 vs. 18.7 months), ORR (18.2% vs. 19.2%), and DCR (78.8% vs, 84.6%) were also similar between the two groups. No new safety signals were observed.ConclusionIn this real-world setting, patients treated with continued ICIs beyond their first disease progression did not experience clinical benefit but without compromising safety.
Keywords
- immune checkpoint inhibitors
- disease progression
- second-line therapy
- non-small-cell lung cancer
- clinical benefit